Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015, Sequent Scientific has informed that the Board of Directors based on the recommendation of the Nomination and Remuneration Committee held on August 07, 2023, approved the appointment of Dr. Hari Babu Bodepudi (DIN: 01119678) as Additional Director (Non?Executive Non?Independent) with effect from August 07, 2023. Dr. Hari Babu Bodepudi will hold office until the conclusion of the ensuing Annual General Meeting of the Company and the Company will be seeking approval of the shareholders at the ensuing Annual General Meeting. Brief profile and other Information of aforesaid Director pursuant to SEBI Circular bearing reference SEBI/HO/CFD/CFD?PoD?1/P/CIR/2023/123 dated July 13, 2023 is mentioned in ‘Annexure A’ as enclosed.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: